Q32 Bio Inc.
QTTB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.03 | -0.17 | 0.07 |
| FCF Yield | -161.56% | -273.94% | -18.59% | -16.47% |
| EV / EBITDA | 0.38 | -0.98 | -1.88 | -2.02 |
| Quality | ||||
| ROIC | -83.11% | -16.41% | -106.80% | -133.29% |
| Gross Margin | 0.00% | 108.69% | 60.92% | 71.91% |
| Cash Conversion Ratio | 1.42 | 0.35 | 0.26 | 1.15 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | – | 35.02% | 173.20% |
| Free Cash Flow Growth | 29.72% | -617.59% | 59.43% | 66.21% |
| Safety | ||||
| Net Debt / EBITDA | 1.30 | -0.24 | -0.02 | 0.32 |
| Interest Coverage | -220.34 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 1.49 | 12.41 |
| Cash Conversion Cycle | -2,240.22 | -2,042.23 | 102.63 | -63.16 |